Tyra Biosciences, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TYRA research report →
Companywww.tyra.bio
Tyra Biosciences, Inc. , a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer.
- CEO
- Todd Harris
- IPO
- 2021
- Employees
- 60
- HQ
- Carlsbad, CA, US
Price Chart
Valuation
- Market Cap
- $2.03B
- P/E
- -16.08
- P/S
- 0.00
- P/B
- 5.44
- EV/EBITDA
- -14.01
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -42.66%
- ROIC
- -36.34%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-119,947,000 · -38.70%
- EPS
- $-2.01 · -33.11%
- Op Income
- $-132,762,000
- FCF YoY
- -35.27%
Performance & Tape
- 52W High
- $40.65
- 52W Low
- $8.75
- 50D MA
- $36.08
- 200D MA
- $24.27
- Beta
- 0.79
- Avg Volume
- 1.07M
Get TickerSpark's AI analysis on TYRA
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 5, 26 | Warner Douglas J | other | 85,000 |
| May 5, 26 | Warner Douglas J | other | 25,000 |
| May 5, 26 | Fuhrman Alan | other | 67,000 |
| May 5, 26 | Fuhrman Alan | other | 20,000 |
| May 5, 26 | Harris Todd | other | 79,000 |
| May 5, 26 | Harris Todd | other | 265,000 |
| May 5, 26 | Ashar Bhavesh | other | 50,295 |
| May 5, 26 | Ashar Bhavesh | other | 15,013 |
| May 5, 26 | Rueb Yuliya | other | 8,333 |
| May 5, 26 | Rueb Yuliya | other | 28,000 |
Our TYRA Coverage
We haven't published any research on TYRA yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate TYRA Report →